(2) Traditional Device Pass-Through Applications (a) Axoguard HA+ Nerve Protector TM Axogen Corporation submitted an application for a new device category for transitional pass-through payment status for the Axoguard HA+ Nerve Protector TM for CY 2026
Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products
it away from heat, moisture, and direct sunlight to preserve its stability
For example, adding 1mL more to an existing 2mL reconstitution gives you 3mL total, yielding a 3.33mg/mL concentration
Reports may include testing from independent laboratories such as Janoshik, Chromate, and Freedom Diagnostics, depending on the batch
[9] Therefore, unless the mother has a clear deficiency, routine use of the B-Complex Injection during breastfeeding may be unnecessary